Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thCompany Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTThe Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business UpdateTreatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025...
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured CompanyPhase 1b Trial Reported Approximately 65% Pathological Response in cSCC, Including Complete Responses at Maximum Dose, With No Serious Adverse Events
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured CompanySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and...
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer TrialMaximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in...
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery ConferenceKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. -...
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 CongressKing of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateClinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive...
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award ProgramKing of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biopharmaceutical company...
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks InsideAprea Therapeutics, Inc. (Nasdaq: APRE) is a clinical-stage biopharmaceutical company pioneering a new era in precision oncology. By combining deep genetic insight with targeted molecular design, Aprea is advancing therapies that exploit cancer-specific vulnerabilities — aiming to outsmart tumor biology while preserving healthy tissue and improving patient quality of life.
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross ProceedsKing of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company...
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer TrialPathologic Clearance: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater...
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent DirectorKing of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesKing of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesKing of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals to Present at the Life Sciences Future ConferenceKing of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage biopharmaceutical company...
